GlassScriptPhysician profile
Karl S Hurst-Wicker
NPI 1962698654
$8,992.86
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $288 · 2021: $2,363 · 2022: $2,083 · 2023: $1,898 · 2024: $521 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Consulting Fee: $1,000 · Travel and Lodging: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.65 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,344.85 | 2021-2025 | Kyphon Express II Kyphopak Tray, Specify Surescan Mri 5-6-5, Intellis Adaptivestim |
| Spinal Simplicity, LLC | $1,902.09 | 2021-2022 | |
| Zavation Medical Products, LLC | $1,171.64 | 2023 | |
| Nevro Corp. | $935.67 | 2019-2024 | Senza |
| Boston Scientific Corporation | $425.20 | 2019-2025 | Intracept |
| Vertiflex, INC. | $199.42 | 2019 | |
| Medtronic USA, INC. | $181.59 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $146.32 | 2019 | |
| Amgen INC. | $139.52 | 2019-2020 | |
| Relievant Medsystems, INC. | $63.13 | 2020-2023 | Intracept |
| Spr Therapeutics, INC | $56.30 | 2019-2022 | |
| Pacira Therapeutics, INC. | $56.21 | 2019 | |
| Radius Health, INC. | $54.05 | 2019 | |
| Tersera Therapeutics LLC | $46.52 | 2019 | |
| Depuy Synthes Sales INC. | $37.16 | 2022-2023 | Tfn-Advance, Na |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.71 | 2022-2023 | |
| Abbott Laboratories | $31.75 | 2019 | |
| Collegium Pharmaceutical, INC. | $30.28 | 2019-2023 | Xtampza |
| Vertos Medical, INC. | $29.80 | 2019 | |
| Flowonix Medical Incorporated | $24.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.01 | 2019 | |
| Bioventus LLC | $19.26 | 2019 | |
| Olympus America INC. | $19.18 | 2024 | Single Use Repositionable Clip |
| Daiichi Sankyo INC. | $17.96 | 2019 | |
| Stratus Medical, LLC | $7.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Hurst-Wicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.